[HTML][HTML] Dural lymphatics regulate clearance of extracellular tau from the CNS

TK Patel, LM Habimana-Griffin, X Gao, B Xu… - Molecular …, 2019 - Springer
TK Patel, LM Habimana-Griffin, X Gao, B Xu, S Achilefu, K Alitalo, CA McKee, PW Sheehan
Molecular neurodegeneration, 2019Springer
Background Alzheimer's disease is characterized by two main neuropathological hallmarks:
extracellular plaques of amyloid-β (Aβ) protein and intracellular aggregates of tau protein.
Although tau is normally a soluble monomer that bind microtubules, in disease it forms
insoluble, hyperphosphorylated aggregates in the cell body. Aside from its role in AD, tau is
also involved in several other neurodegenerative disorders collectively called tauopathies,
such as progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), some …
Background
Alzheimer’s disease is characterized by two main neuropathological hallmarks: extracellular plaques of amyloid-β (Aβ) protein and intracellular aggregates of tau protein. Although tau is normally a soluble monomer that bind microtubules, in disease it forms insoluble, hyperphosphorylated aggregates in the cell body. Aside from its role in AD, tau is also involved in several other neurodegenerative disorders collectively called tauopathies, such as progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), some forms of frontotemporal dementia, and argyrophilic grain disease (AGD). The prion hypothesis suggests that after an initial trigger event, misfolded forms of tau are released into the extracellular space, where they spread through different brain regions, enter cells, and seeding previously normal forms. Thus understanding mechanisms regulating the clearance of extracellular tau from the CNS is important. The discovery of a true lymphatic system in the dura and its potential role in mediating Aβ pathology prompted us to investigate its role in regulating extracellular tau clearance.
Methods
To study clearance of extracellular tau from the brain, we conjugated monomeric human tau with a near-infrared dye cypate, and injected this labeled tau in the parenchyma of both wild-type and K14-VEGFR3-Ig transgenic mice, which lack a functional CNS lymphatic system. Following injection we performed longitudinal imaging using fluorescence molecular tomography (FMT) and quantified fluorescence to calculate clearance of tau from the brain. To complement this, we also measured tau clearance to the periphery by measuring plasma tau in both groups of mice.
Results
Our results show that a significantly higher amount of tau is retained in the brains of K14-VEGFR3-Ig vs. wild type mice at 48 and 72 h post-injection and its subsequent clearance to the periphery is delayed. We found that clearance of reference tracer human serum albumin (HSA) was also significantly delayed in the K14-VEGFR3-Ig mice.
Conclusions
The dural lymphatic system appears to play an important role in clearance of extracellular tau, since tau clearance is impaired in the absence of functional lymphatics. Based on our baseline characterization of extracellular tau clearance, future studies are warranted to look at the interaction between tau pathology and efficiency of lymphatic function.
Springer